Apexigen, Inc.
DelistedCIK 1814140fmd_108GB62T2E5Z8827VV1PDT0P8GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2020 to Jun 30, 2023, 11 periods
Latest annual · FY2022
Millions- Operating income
- (33)
- Net income
- (32)
- Free cash flow
- (31)
Latest quarter · Q2 FY2023
Millions- Operating income
- (6)
- Net income
- (6)
- Free cash flow
- (3)
Apexigen, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$32.7 million | -$29 million | 10-K 2023-02-22 · proof | |
| Net income | -$32.1 million | -$28.9 million | 10-K 2023-02-22 · proof | |
| Cash from operating activities | -$30.7 million | -$23.9 million | 10-K 2023-02-22 · proof | |
| Free cash flow | -$30.8 million | -$24 million | 10-K 2023-02-22 · proof | |
| Total assets | $22.9 million | $39.1 million | -41.5% | 10-K 2023-02-22 · proof |
| Total liabilities | $16.5 million | $17.1 million | -3.6% | 10-K 2023-02-22 · proof |
| Cash and cash equivalents | $14.8 million | $23.4 million | -36.9% | 10-K 2023-02-22 · proof |
- What was Apexigen, Inc.'s operating income in fiscal 2022?
- Apexigen, Inc. reported operating income of -$32.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$29 million the year before. Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What was Apexigen, Inc.'s net income in fiscal 2022?
- Apexigen, Inc. reported net income of -$32.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$28.9 million the year before. Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What was Apexigen, Inc.'s cash from operating activities in fiscal 2022?
- Apexigen, Inc. reported cash from operating activities of -$30.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$23.9 million the year before. Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What was Apexigen, Inc.'s free cash flow in fiscal 2022?
- Apexigen, Inc. reported free cash flow of -$30.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$24 million the year before. Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What are Apexigen, Inc.'s total assets?
- As of Dec 31, 2022, Apexigen, Inc. reported total assets of $22.9 million, against $39.1 million a year earlier (-41.5%). Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What are Apexigen, Inc.'s total liabilities?
- As of Dec 31, 2022, Apexigen, Inc. reported total liabilities of $16.5 million, against $17.1 million a year earlier (-3.6%). Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
- What are Apexigen, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Apexigen, Inc. reported cash and cash equivalents of $14.8 million, against $23.4 million a year earlier (-36.9%). Source: the 10-K filed with the SEC on Feb 22, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1814140&period_type=annual&limit=5"Information only, not investment advice.